First Interstate Bank bought a new stake in Omeros Corporation (NASDAQ:OMER) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,000 shares of the biopharmaceutical company’s stock, valued at approximately $108,000.
Several other large investors have also recently bought and sold shares of OMER. EAM Investors LLC bought a new position in shares of Omeros Corporation in the second quarter valued at approximately $3,083,000. Quantitative Investment Management LLC bought a new position in Omeros Corporation in the 2nd quarter worth approximately $2,979,000. Chicago Equity Partners LLC raised its position in Omeros Corporation by 268.3% in the 3rd quarter. Chicago Equity Partners LLC now owns 195,875 shares of the biopharmaceutical company’s stock worth $4,235,000 after purchasing an additional 142,695 shares during the last quarter. Stifel Financial Corp raised its position in Omeros Corporation by 54.1% in the 2nd quarter. Stifel Financial Corp now owns 356,160 shares of the biopharmaceutical company’s stock worth $7,091,000 after purchasing an additional 125,110 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Omeros Corporation by 5.4% in the 2nd quarter. Vanguard Group Inc. now owns 1,825,671 shares of the biopharmaceutical company’s stock worth $36,341,000 after purchasing an additional 94,280 shares during the last quarter. Institutional investors own 45.38% of the company’s stock.
WARNING: This piece was first published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://transcriptdaily.com/2017/11/22/first-interstate-bank-takes-position-in-omeros-corporation-omer.html.
OMER has been the subject of several research analyst reports. Cantor Fitzgerald restated a “hold” rating and issued a $19.00 price objective (up previously from $15.00) on shares of Omeros Corporation in a research report on Thursday, August 24th. Zacks Investment Research lowered shares of Omeros Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Maxim Group set a $24.00 target price on shares of Omeros Corporation and gave the stock a “buy” rating in a report on Friday, October 20th. Wedbush reaffirmed an “outperform” rating and set a $47.00 target price on shares of Omeros Corporation in a report on Friday, August 18th. Finally, HC Wainwright initiated coverage on shares of Omeros Corporation in a report on Wednesday, November 8th. They set a “buy” rating and a $30.00 target price for the company. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $34.14.
Shares of Omeros Corporation (OMER) traded down $0.26 during mid-day trading on Wednesday, hitting $18.26. 598,600 shares of the stock traded hands, compared to its average volume of 805,659. Omeros Corporation has a one year low of $8.71 and a one year high of $27.09. The company has a debt-to-equity ratio of 8.99, a current ratio of 4.77 and a quick ratio of 4.74.
Omeros Corporation (NASDAQ:OMER) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.18. The company had revenue of $21.66 million during the quarter, compared to analyst estimates of $17.82 million. Omeros Corporation’s revenue for the quarter was up 91.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.34) earnings per share. equities analysts expect that Omeros Corporation will post -1.07 EPS for the current fiscal year.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.